Hrt Financial LP Immuno Gen, Inc. Transaction History

Hrt Financial LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$3.75 - $20.05 $1.21 Million - $6.46 Million	322,121 New	322,121 $6.08 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $1.62 Million - $2.34 Million	361,353 New	361,353 $1.73 Million
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $182,034 - $319,627	-42,731 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $733,428 - $1.16 Million	-154,406 Reduced 78.32%	42,731 $317,000
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $989,627 - $1.3 Million	197,137 New	197,137 $1.12 Million
Q2 2021 Aug 16, 2021	SELL	$5.79 - $8.6 $298,636 - $443,570	-51,578 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $335,257 - $543,116	51,578 New	51,578 $417,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $212,021 - $323,761	-95,505 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.8 - $3.3 $171,909 - $315,166	95,505 New	95,505 $207,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.